title: New approaches in the pharmacologic treatment of portal hypertension.
abstract: To alleviate the risk of variceal bleeding, the portal pressure gradient--usually evaluated as the hepatic venous pressure gradient (HVPG)--must be reduced to < or = 12 mmHg. Although beta-blocking agents are accepted therapy for preventing first or subsequent bleeding episodes, propranolol therapy decreases final HVPG to < or = 12 mmHg in only 12% of patients, while only 24% of patients have a > or = 20% reduction in HVPG and nearly 40% show no reduction in HVPG. This has stimulated research on alternative or additional treatments. Nitrates such as isosorbide dinitrate reduce portal pressure by decreasing resistance to portal and collateral blood flow and by promoting reflex splanchnic vasoconstriction. However, while nitrates are effective in the acute situation, tolerance leading to refractoriness develops over the long term unless they are combined with diuretics or other agents in the treatment of portal hypertension. Propranolol and isosorbide-5-mononitrate combined cause a substantially greater reduction in HVPG than monotherapy with either drug in both acute and long-term use. Presumably concomitant isosorbide-5-mononitrate administration opposes the increase in portal resistance induced by propranolol. Spironolactone, which has been shown to lower HVPG in patients with cirrhosis, produces a reduction in plasma volume that attenuates the increased cardiac output associated with cirrhosis and triggers vasoactive mechanisms that decrease splanchnic blood flow. Potentially, spironolactone may maintain and enhance the decrease in portal pressure achieved by nitrates or propranolol. Triple therapy with a beta-blocker, a nitrate and spironolactone may be feasible.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Hepatic Haemodynamics Laboratory, Hospital Clinic i Provincial, University of Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Bosch
authors.forename: J C
authors.initials: JC
authors.lastname: García-Pagán
authors.forename: F
authors.initials: F
authors.lastname: Feu
authors.forename: A
authors.initials: A
authors.lastname: Luca
authors.forename: M
authors.initials: M
authors.lastname: Fernández
authors.forename: P
authors.initials: P
authors.lastname: Pizcueta
authors.forename: J
authors.initials: J
authors.lastname: Rodés
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D011433:Propranolol / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D012702:Serotonin Antagonists; D013148:Spironolactone; D011433:Propranolol